|3.||Endometrial Neoplasms (Endometrial Cancer)
|1.||Gupta, Janesh K: 9 articles (11/2013 - 04/2006)|
|2.||Archer, David F: 7 articles (07/2015 - 08/2002)|
|3.||Gallos, Ioannis D: 7 articles (11/2013 - 03/2010)|
|4.||Broaddus, Russell R: 7 articles (08/2013 - 09/2002)|
|5.||Ørbo, Anne: 6 articles (12/2015 - 06/2005)|
|6.||Ganesan, Raji: 6 articles (11/2013 - 08/2008)|
|7.||Reed, Susan D: 6 articles (01/2013 - 07/2008)|
|8.||Yaegashi, Nobuo: 6 articles (01/2012 - 06/2002)|
|9.||Saito, Tsuyoshi: 6 articles (07/2007 - 03/2002)|
|10.||Arnes, Marit: 5 articles (12/2015 - 05/2006)|
|1.||Levonorgestrel (Plan B)FDA LinkGeneric
09/01/2008 - "The levonorgestrel-releasing intrauterine system seems to be an effective and safe alternative in the treatment of peri- and postmenopausal women with (simple) endometrial hyperplasia without atypia."
06/01/2015 - "Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia."
01/01/2013 - "Randomised controlled trials (RCTs) of the levonorgestrel-releasing intrauterine system (LNG-IUS) versus progestin therapy in women with a confirmed histological diagnosis of simple or complex endometrial hyperplasia with atypia. "
11/01/2011 - "The objective of this study was to evaluate the potential treatment of atypical and non-atypical endometrial hyperplasia with the levonorgestrel intrauterine system (LNG-IUS). "
06/01/2011 - "Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006)."
01/01/2011 - "Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia."
01/01/2004 - "The addition of progestogens, either in continuous combined or sequential regimens, helped to reduce the risk of endometrial hyperplasia and improved adherence to therapy. "
01/01/2000 - "The addition of progestogens, either in continuous combined or sequential regimens, helped to prevent the development of endometrial hyperplasia and improved adherence to therapy (odds ratios of 3.7 for sequential therapy and 6.0 for continuous therapy). "
10/01/2011 - "We carried out a web-based survey of all UK consultant gynaecologists, from the Royal College of Obstetricians and Gynaecologists (RCOG) database, to evaluate the current practice and to enquire whether a trial between oral progestogens and LNG-IUS for endometrial hyperplasia is required. "
06/01/2001 - "By 1959, initial studies demonstrated the ability of progestins to reverse endometrial hyperplasias. "
|3.||Estradiol (Estrace)FDA LinkGeneric
12/01/1996 - "Recent studies have shown that the LNG-IUS is effective in preventing endometrial proliferation associated with oral or transdermal estradiol therapy, and in inducing regression of endometrial hyperplasia. "
11/01/2009 - "The treatment using Xianling Gubao capsules for patients with menopause syndrome could improve the clinic symptoms, increase the serous estradiol level, but do not increase the risk of endometrial hyperplasia."
09/01/2004 - "Postmenopausal treatment with low-dose, unopposed estradiol increased bone mineral density and decreased markers of bone turnover without causing endometrial hyperplasia."
09/01/2004 - "Endometrial hyperplasia developed in 1 woman in the estradiol group but in none of the placebo group (difference in 2-year rates 0.5%, 95% confidence interval 0-7.3%). "
03/28/2003 - "Endometrial hyperplasia caused by the unopposed use of estradiol during menopause probably harbors fewer genomic errors than those cases occurring spontaneously."
|4.||Estrogens (Estrogen)FDA Link
07/01/2000 - "Concurrent administration of a progestin to protect women from the risk of endometrial hyperplasia may alter the protective effects of estrogen. "
03/01/2006 - "Further, it has been shown to provide protection against endometrial hyperplasia associated with unopposed estrogen therapy."
11/01/2003 - "Efficacy of lower doses of CEE/MPA in reducing the incidence of endometrial hyperplasia rates associated with unopposed estrogen (E). "
09/01/2007 - "A greater incidence of simple, low-grade endometrial hyperplasia was found in our study compared with studies using continuous estrogen/progestin regimens. "
01/01/2006 - "Moreover, a recently published 2-year study of ultra-low-dose transdermal estrogen monotherapy in an older population similar to that of the WHI reported significant increases in bone mineral density, accompanied by significant reductions in markers of bone turnover, with no increased risk of endometrial hyperplasia or other side effects. "
04/01/1989 - "Both of the drugs were effective and safe alternative therapy for endometrial hyperplasia to progesterone."
03/01/2006 - "In this prospective control study, endometrial tissue samples of 19 patients with simple endometrial hyperplasia without atypia (group 1), posttreatment biopsy materials of the patients after 3 months of cyclic progesterone treatment with noretisterone for 10 days (group 2), and 18 endometrial biopsy materials of the control group (group 3) were examined for proliferative and apoptotic activities. "
03/01/2006 - "The aim of this study was to evaluate the effect of long-term use of progesterone treatment on proliferation and apoptosis in simple endometrial hyperplasia without atypia. "
01/01/2001 - "The aims of this study were: (i) to establish a reliable model for the study of cystic endometrial hyperplasia in ovariectomized bitches; and (ii) to assess the roles of oestrogen and progesterone in the pathogenesis of irritant-induced cystic endometrial hyperplasia. "
01/01/2012 - "Medical treatment with progesterone containing drugs addresses endometrial hyperplasia without atypia. "
|6.||Danazol (Azol)FDA LinkGeneric
01/01/1986 - "This study was performed to verify the efficacy of Danazol on the treatment of endometrial hyperplasia in postmenopausal patients. "
09/01/2000 - "However, mechanisms of direct effect of danazol on endometrial hyperplasia remain to be elucidated in the future study."
10/01/2000 - "At 30 weeks, incidences of atypical and complex endometrial hyperplasia were significantly decreased by danazol-treatment. "
02/01/1994 - "To confirm the effectiveness of danazol in the management of simple or complex endometrial hyperplasia without atypical features, as has been demonstrated previously. "
02/01/1994 - "Postmenopausal endometrial hyperplasia: role of danazol therapy."
|7.||anastrozole (Arimidex)FDA LinkGeneric
02/01/2005 - "Anastrozole appears to be an interesting new modality for the treatment of endometrial hyperplasia in obese postmenopausal women."
02/01/2005 - "We administered anastrozole for 12 months to 11 obese postmenopausal women with high operative risk, in order to treat endometrial hyperplasia (four simple, five complex and two atypical). "
10/01/2007 - "Adjuvant therapy with anastrozole may be beneficial in resolving endometrial hyperplasia in patients with breast cancer."
10/01/2007 - "After consultation with the patient's oncologist, the patient received adjuvant anastrozole therapy for the breast cancer; it led to resolution of the endometrial hyperplasia. "
10/01/2007 - "Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report."
01/01/1999 - "[An immunohistochemical study of the steroid hormone receptors in endometrial hyperplasia]."
01/01/1997 - "This method could be used for further receptor studies, particularly in those diseases mediated by steroid hormones such as cystic endometrial hyperplasia and mammary neoplasia."
04/01/2015 - "Current guidelines recommend that hormone therapy (HT) in postmenopausal women with a uterus include a progestin to protect against endometrial hyperplasia. "
01/01/2014 - "Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: a Cochrane review summary."
01/01/2012 - "Hormone therapy in postmenopausal women and risk of endometrial hyperplasia."
|9.||Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric
12/01/2015 - "Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study."
12/01/2015 - "To assess the efficacy, safety and acceptability of cyclic medroxyprogesterone acetate (MPA) compared to continuous MPA for treatment of endometrial hyperplasia (EH) without atypia. "
06/01/2004 - "A 31-year-old woman was treated for atypical endometrial hyperplasia (AEH) with high-dose medroxyprogesterone acetate (MPA) therapy to preserve fertility. "
01/01/1997 - "Furthermore, a significant increase in the uterine fluid hDP 200 level (p < 0.0008) was observed in women with endometrial hyperplasia following treatment with medroxyprogesterone acetate. "
05/01/1994 - "However, none of the patients receiving the two higher medroxyprogesterone acetate dosages (groups B and D) had endometrial hyperplasia. "
|10.||Gonadotropin-Releasing Hormone (GnRH)FDA Link
10/01/1995 - "Our results demonstrate therapeutic efficacy of GnRH analogues in the treatment of endometrial hyperplasia with menometrorrhagia either in premenopausal or menopausal women."
04/01/1997 - "On the basis of the recently reported observation that gonadotropin-releasing hormone agonists (GnRH-a) can affect endometrial cell proliferation, both indirectly, through the hormonal axis, and directly, by acting on the GnRH-a receptors, we investigated how far GnRH-a can be used as a new treatment mode for endometrial hyperplasias. "
10/01/1995 - "[Use of a GnRH analogue in the treatment of certain forms of endometrial hyperplasia associated with menometrorrhagia]."
01/01/1994 - "We have studied endometrial modifications due to LHRH-analogue in 75 patients with AUB and with a hysteroscopic and histologic picture of low-risk endometrial hyperplasia. "
12/01/1993 - "[Therapy of simple endometrial hyperplasia with GnRH analogs. "
|1.||Intrauterine Devices (Intrauterine Device)
04/01/2012 - "Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature."
02/01/2012 - "Oral progestin and progestin-releasing intrauterine devices (IUDs) have been shown to result in regression of endometrial hyperplasia and grade 1 endometrioid endometrial carcinoma. "
01/01/2008 - "The progestin infiltrated intrauterine device used as therapy for endometrial carcinoma as well as endometrial hyperplasia yields a hundred-fold increase of local progestin concentration in the endometrium compared to that of oral treatment. "
03/01/2003 - "Should endometrial hyperplasia be regarded as a reason for abnormal uterine bleeding in users of the intrauterine contraceptive device?"
07/01/1999 - "Angiogenesis is important to cyclic, regenerating endometria and disease processes including dysfunctional uterine bleeding, response to exogenous hormonal treatment, bleeding associated with intrauterine contraceptive devices, uterine leiomyomata, endometriosis, complex endometrial hyperplasia, and endometrial carcinoma. "
|2.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
11/01/2001 - "Sequential combined transdermal hormone replacement therapy is as effective as oral therapy in preventing the development of endometrial hyperplasia. "
07/01/2004 - "However, the relatively high rate of concomitant endometrial hyperplasia, especially in patients receiving hormone replacement therapy, dictates a thorough histological evaluation in all cases."
12/01/2002 - "No increased risk of endometrial hyperplasia with fixed long-cycle hormone replacement therapy after two years."
08/03/2002 - "Continuous combined hormone replacement therapy and endometrial hyperplasia."
07/01/2002 - "As compared with the therapeutic effect of hormone replacement therapy, the risk of carcinogenesis caused by endometrial hyperplasia could be avoided because the blood level of E2 is only slightly increased by BSPY."
12/01/1986 - "This regimen proved to be most effective in preventing hysterectomy in postmenopausal patients who presented with surgical risk factors and endometrial hyperplasia."
11/01/2012 - "Treatment with progestin therapy may provide a safe alternative to hysterectomy; however, clinical trials of hormonal therapies for atypical endometrial hyperplasia or endometrial intraepithelial neoplasia have not yet established a standard regimen. "
12/01/2010 - "This retrospective single-institution study included women who were diagnosed with endometrial hyperplasia (simple or complex) and underwent hysterectomy within 12weeks from the initial diagnosis without interval treatment. "
01/01/2007 - "The objective of this study was to estimate the incidence of atypical endometrial hyperplasia encountered during routine resectoscopic surgery in women with AUB and to evaluate the role of resectoscopic surgery in the management of women with AUB and atypical endometrial hyperplasia who refused and/or were at high risk for hysterectomy. "
02/01/2015 - "The result of an endometrial biopsy was complex endometrial hyperplasia with atypia, and a robotic-assisted laparoscopic hysterectomy was performed. "
10/01/2015 - "Comparison of diagnostic accuracy between endometrial curettage and pipelle aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group Study (KGOG 2019)."
07/01/2008 - "A 2-member panel reviewed 209 endometrial biopsy/curettage specimens originally diagnosed as incident endometrial hyperplasia as part of a progression study. "
09/01/1999 - "A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens."
01/01/2014 - "Endometrial pathology was defined as simple, irregular, or complex endometrial hyperplasia by a pathologist after curettage. "
09/01/2009 - "The diagnosis of complex atypical endometrial hyperplasia was biopsy-based for 531 (73%) and curettage-based for 193 (27%). "
|5.||Dilatation and Curettage (D&C)
10/01/2015 - "A prospective multicenter trial has been started in Korea to evaluate the diagnostic accuracy of endometrial aspiration biopsy compared with dilatation and curettage in patients treated with progestin for endometrial hyperplasia. "
01/01/2014 - "Neither Pipelle biopsy nor D&C was adequate for detecting focal endometrial pathologies and endometrial hyperplasia. "
01/01/2003 - "A 53-year-old women underwent D & C and diagnostic hysteroscopy for suspected endometrial hyperplasia, when the posterior uterine wall was perforated. "
01/01/1997 - "63 cases of adenomatous endometrial hyperplasia (1st-3rd degree) were diagnosed by hysteroscopy and D&C at the Department of Obstetrics and Gynaecology of the University of Greifswald from January 1991 to December 1994. "
01/01/1996 - "In the presented study a group of 140 postmenopausal women has been evaluated and in 10 patients the sonography disclosed endometrial thickness of more than 12 mm. Biopsy in the study group revealed three cases of endometrial hyperplasia and all they were in the patients with uterine lining thicker than 12 mm. In patients taking hormone replacement therapy endometrial thickness of more than 12 mm should be regarded as indication for D&C."